{"cursor":"25269","size":15,"audio":[],"currentlang":"en","article":"{{drugbox\n| Verifiedfields = changed verifiedrevid = 458271995 image =\n| Infliximab_structure2.jpg\n\n\n| type = mab mab_type = mab source = xi/o target = TNF\n\n\n| tradename = Remicade Drugs.com = pregnancy_category = B legal_US = Rx-only\n| legal_status = routes_of_administration = IV\n\n\n| bioavailability = 92% (IV, if 8% left in the syringe) protein_bound =\n| metabolism = reticuloendothelial system elimination_half-life = 9.5 days\n\n\n| ChemSpiderID_Ref = ChemSpiderID = NA CAS_number_Ref = CAS_number = 170277-31-3\n| ATC_prefix = L04 ATC_suffix = AB02 ATC_supplemental = PubChem = DrugBank_Ref =\n| DrugBank = DB00065 UNII_Ref = UNII = B72HH48FLU KEGG_Ref = KEGG = D02598\n| ChEMBL_Ref = ChEMBL = 1201581\n\n\n| C=6428 | H=9912 | N=1694 | O=1987 | S=46 molecular_weight = 144190.3 g/mol\n}}\n\n\n'Infliximab' (INN; trade name 'Remicade') is a monoclonal antibody against\ntumour necrosis factor alpha (TNF-Î±) used to treat autoimmune diseases. Remicade\nis marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the\nUSA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-\nPlough (now part of Merck & Co) elsewhere.\n{{cite press release\n| title = Remicade Becomes First Anti-TNF Biologic Therapy to Treat One Million\n| Patients Worldwide url = http://www.jnj.com/connect/NewsArchive/all-news-\n| archive/20071106_141812 publisher = Johnson & Johnson date = November 6, 2007\n| accessdate = 2009-11-14\n}}\n\nInfliximab was approved by the U.S. Food and Drug Administration (FDA) for the\ntreatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic\narthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its\ninitial approval by the FDA for the treatment of Crohn's disease in August\n1998. {{cite web\n| url = http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelop-\n| edandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327-\n| .htm title = Infliximab Product Approval Information - Licensing Action work\n| = Drugs@FDA publisher = U.S. Food and Drug Administration (FDA) accessdate =\n| 2009-11-14\n}}\n\nInfliximab works by binding to tumour necrosis factor alpha. TNF-Î± is a chemical\nmessenger (cytokine) and a key part of the autoimmune reaction. Originally, the\naction of infliximab (in rheumatoid arthritis) was assumed to work by blocking\nthe action of TNF-Î± by preventing it from binding to its receptor in the cell.\nThis still seems to be true. However, another TNF-Î±-neutralizing medication,\netanercept (Enbrel), is worse than a placebo in Crohn's disease, so TNF-Î±-\nneutralisation is not responsible for its powerful action in the latter\ndisease. {{cite journal\n| author = Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ title = Treating\n| Crohn's disease by inducing T lymphocyte apoptosis journal = Ann. N. Y. Acad.\n| Sci. volume = 973 issue = pages = 166â80 year = 2002 month = November doi =\n| 10.1111/j.1749-6632.2002.tb04628.x pmid = 12485856\n}} Infliximab causes programmed cell death of TNF-Î±-expressing activated\nT lymphocytes, an important cell type mediating inflammation, but etanercept\ndoes not have this activity; now, resolution of activated T cells by\ninfliximab is generally assumed to explain its efficacy in Crohn's\ndisease. {{cite journal\n| author = Van den Brande JM title = Infliximab but not etanercept induces\n| apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease\n| journal = Gastroenterology volume = 124 issue = 7 pages = 1774â85 year = 2003\n| month = July doi = 10.1016/S0016-5085(03)00382-2 pmid = 12806611 author-\n| separator = , display-authors = 3\n}}\n\nInfliximab is an artificial antibody. It was originally developed in mice as a\nmouse antibody. Because humans have immune reactions to mouse proteins, the\nmouse common domains were replaced with similar human antibody domains. Because\nthe antibodies were produced from one cell grown into a clone of identical\ncells, it is called a monoclonal antibody. Furthermore, as a combination of\nmouse and human antibody amino acid sequences, it is called a chimeric\nmonoclonal antibody.\n\nInfliximab was developed by Junming Le and Jan Vilcek at New York University\nSchool of Medicine and developed by Centocor, (now Janssen Biotech, Inc.)\n{{cite journal\n| author = Knight DM title = Construction and initial characterization of a mouse-\n| human chimeric anti-TNF antibody journal = Mol. Immunol. volume = 30 issue =\n| 16 pages = 1443â53 year = 1993 month = November doi = 10.1016/0161-5890(93)90106-\n| L pmid = 8232330 author-separator = , author2 = Trinh H author3 = Le J display-\n| authors = 3 last4 = Siegel first4 = Scott last5 = Shealy first5 = David last6\n| = McDonough first6 = Margaret last7 = Scallon first7 = Bernard last8 = Moore\n| first8 = Maria Arevalo last9 = Vilcek first9 = Jan\n}}\n\nInfliximab can cost $19,000 to $22,000 a year per patient wholesale, according\nto Centocor. [http://www.sfgate.com/cgi-\nbin/article.cgi?f=/c/a/2007/05/08/BUGHAPMN021.DTL \"Priced out of pain relief;\nInsurers balk at high costs of promising new treatments\"], Victoria Colliver,\n[[San Francisco Chronicle]], May 8, 2007 It is typically covered under\nmajor medical insurance (rather than prescription drug insurance).\n\nOther monoclonal antibodies targeting TNF-Î± are golimumab (Simponi), adalimumab\n(Humira), and certolizumab pegol (Cimzia). Etanercept also binds and inhibits\nthe action of TNF-Î±, but is not a monoclonal antibody (it is instead a fusion of\nTNF-receptor and an antibody constant region).\n\nInfliximab is administered by intravenous infusion, typically at six- to eight-\nweek intervals, at a clinic or hospital. It cannot be administered orally\nbecause the digestive system would destroy the drug.\n","linknr":748,"url":"remicade","recorded":1364030203,"links":["/w/index.php?title=Infliximab&action=edit","/w/index.php?title=Infliximab&action=edit","//en.wikipedia.org/apple-touch-icon.png","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","/wiki/Infliximab","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","/w/index.php?title=Remicade&redirect=no","#mw-head","#p-search","/wiki/Nomenclature_of_monoclonal_antibodies","/wiki/File:Infliximab_structure2.jpg","//upload.wikimedia.org/wikipedia/commons/thumb/5/5c/Infliximab_structure2.jpg/220px-Infliximab_structure2.jpg","/wiki/Monoclonal_antibody#Applications","/wiki/File:Engineered_monoclonal_antibodies.svg","/wiki/Monoclonal_antibody#Production","/wiki/Chimeric_antibody","/wiki/Mouse","/wiki/Human","/wiki/Antigen","/wiki/Tumor_necrosis_factors","/wiki/Trade_name","/wiki/American_Society_of_Health-System_Pharmacists","/wiki/Drugs.com","http://www.drugs.com/monograph/infliximab.html","/wiki/Pregnancy_category","/wiki/Regulation_of_therapeutic_goods","/wiki/Prescription_drug","/wiki/United_States","/wiki/Route_of_administration","/wiki/Bioavailability","/wiki/Drug_metabolism","/wiki/Reticuloendothelial","/wiki/Biological_half-life","/wiki/CAS_registry_number","http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=170277-31-3&rn=1","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/Anatomical_Therapeutic_Chemical_Classification_System","/wiki/ATC_code_L04","http://www.whocc.no/atc_ddd_index/?code=L04AB02","/wiki/DrugBank","http://www.drugbank.ca/drugs/DB00065","/wiki/Unique_Ingredient_Identifier","http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/KEGG","http://www.kegg.jp/entry/D02598","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/ChEMBL","https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201581","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/Chemical_formula","/wiki/Carbon","/wiki/Hydrogen","/wiki/Nitrogen","/wiki/Oxygen","/wiki/Sulfur","/wiki/Molecular_mass","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation","//en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271995&page2=Infliximab","//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png","/wiki/Wikipedia:Cleanup","/wiki/Wikipedia:Manual_of_Style","/wiki/Template:Cleanup/doc","//en.wikipedia.org/w/index.php?title=Infliximab&action=edit","/wiki/International_Nonproprietary_Name","/wiki/Monoclonal_antibody","/wiki/TNF_alpha","/wiki/Autoimmune","/wiki/List_of_autoimmune_diseases","/wiki/Centocor","/wiki/Mitsubishi_Tanabe_Pharma","/w/index.php?title=Xian_Janssen&action=edit&redlink=1","/wiki/Schering-Plough","/wiki/Merck_%26_Co","#cite_note-JNJ_20071106_141812-1","/wiki/Food_and_Drug_Administration_(United_States)","/wiki/Psoriasis","/wiki/Crohn%27s_disease","/wiki/Ankylosing_spondylitis","/wiki/Psoriatic_arthritis","/wiki/Rheumatoid_arthritis","/wiki/Ulcerative_colitis","/wiki/Crohn%27s_disease","#cite_note-2","/wiki/Cytokine","/wiki/Receptor_(biochemistry)","/wiki/Etanercept","#cite_note-3","/wiki/Programmed_cell_death","/wiki/T_lymphocytes","#cite_note-4","/wiki/Antibody","/wiki/Monoclonal_antibody","/wiki/Jan_Vilcek","/wiki/New_York_University_School_of_Medicine","/wiki/Centocor","#cite_note-5","#cite_note-6","/wiki/Golimumab","/wiki/Adalimumab","/wiki/Certolizumab_pegol","/wiki/CD120","/wiki/Fc_region","#cite_note-7","/wiki/Intravenous_therapy","/wiki/Route_of_administration","/wiki/Digestive_system","#cite_note-8","#Medical_uses","#Crohn.27s_disease","#Fistulizing_disease","#Inflammatory_disease","#Ulcerative_colitis","#Other","#Adverse_effects","#Pharmacology","#Availability.2Faffordability","#See_also","#External_links","#References","/w/index.php?title=Infliximab&action=edit&section=1","/w/index.php?title=Infliximab&action=edit&section=2","/wiki/Phenotype","/wiki/Crohn%27s_disease","/wiki/Fistula","/wiki/Inflammation","#cite_note-phenotypes-9","/w/index.php?title=Infliximab&action=edit&section=3","/wiki/Skin","/wiki/Bowel","#cite_note-Present-10","/wiki/Placebo","#cite_note-ACCENT2-11","/w/index.php?title=Infliximab&action=edit&section=4","/wiki/File:CD_colitis.jpg","//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/CD_colitis.jpg/220px-CD_colitis.jpg","/wiki/File:CD_colitis.jpg","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/magnify-clip.png","/wiki/Crohn%27s_disease","/wiki/Peptic_ulcer","/wiki/Colonoscopy","#cite_note-ACCENT1-12","/wiki/Prednisone","/wiki/Remission_(medicine)","#cite_note-topdown-13","/w/index.php?title=Infliximab&action=edit&section=5","/wiki/Tumour_necrosis_factor","/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells","/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells","#cite_note-ACT-14","/w/index.php?title=Infliximab&action=edit&section=6","/wiki/COPD","#cite_note-15","/wiki/Beh%C3%A7et%27s_disease","#cite_note-16","/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items","#cite_note-17","/wiki/Enthesitis","#cite_note-18","/w/index.php?title=Infliximab&action=edit&section=7","//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","//en.wikipedia.org/w/index.php?title=Infliximab&action=edit","/wiki/Help:Introduction_to_referencing/1","/wiki/Template:Citation_needed","/wiki/Wikipedia:Verifiability#Burden_of_evidence","/wiki/Remicade","/wiki/Enbrel","/wiki/Humira","/wiki/Immunosuppressants","/wiki/Blood_disorder","/wiki/Infection","/wiki/Lymphoma","/wiki/Hepatitis_B","/wiki/Tuberculosis","#cite_note-19","/wiki/Hepatosplenic_T-cell_lymphoma","/wiki/Lupus","/wiki/Demyelinating","/wiki/Central_nervous_system","/wiki/Psoriasis","/wiki/Vitiligo","/wiki/Leukopenia","/wiki/Neutropenia","/wiki/Thrombocytopenia","/wiki/Pancytopenia","#cite_note-20","#cite_note-21","#cite_note-22","/wiki/Methotrexate","#cite_note-23","#cite_note-ACCENT1-12","/wiki/Azathioprine","/wiki/Psoriasis","/wiki/Psoriatic_arthritis","/wiki/Ankylosing_spondylitis","/wiki/Rheumatoid_arthritis","/w/index.php?title=Infliximab&action=edit&section=8","/wiki/TNF_alpha","/wiki/Affinity_(pharmacology)","/wiki/T_cells","/wiki/Adalimumab","/wiki/Transmembrane","/wiki/Receptor_(immunology)","#cite_note-24","#cite_note-25","/wiki/Adalimumab","/wiki/Lysing","#cite_note-26","/wiki/Specificity_(tests)","/wiki/Lymphotoxin","/wiki/Proinflammatory","/wiki/Cytokine","/wiki/Interleukin","/wiki/Leukocyte","/wiki/Endothelial","/wiki/Adhesion_molecule","/wiki/Transgenic","/w/index.php?title=Infliximab&action=edit&section=9","/wiki/Wikipedia:Citation_needed","#cite_note-27","#cite_note-JNJ_20071106_141812-1","#cite_note-JNJ_20071106_141812-1","#cite_note-28","/wiki/Crohn%27s_Disease_Activity_Index","#cite_note-29","/w/index.php?title=Infliximab&action=edit&section=10","/wiki/Biological_therapy_for_inflammatory_bowel_disease","/w/index.php?title=Infliximab&action=edit&section=11","http://www.remicade.com/","http://www.nras.org.uk/about_rheumatoid_arthritis/newly_diagnosed/which_drugs_are_used/antitnfa_treatment_in_rheumatoid_arthritis.aspx","http://www.druglib.com/druginfo/remicade/","http://www.remicade.com/remicade/global/hcp/hcp_pi.html","/w/index.php?title=Infliximab&action=edit&section=12","#cite_ref-JNJ_20071106_141812_1-0","#cite_ref-JNJ_20071106_141812_1-1","#cite_ref-JNJ_20071106_141812_1-2","http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812","/wiki/Johnson_%26_Johnson","http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812","#cite_ref-2","http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htm","/wiki/Food_and_Drug_Administration_(United_States)","http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htm","#cite_ref-3","/wiki/Digital_object_identifier","http://dx.doi.org/10.1111%2Fj.1749-6632.2002.tb04628.x","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12485856","#cite_ref-4","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2FS0016-5085%2803%2900382-2","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12806611","#cite_ref-5","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2F0161-5890%2893%2990106-L","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/8232330","#cite_ref-6","http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2007/05/08/BUGHAPMN021.DTL","/wiki/San_Francisco_Chronicle","#cite_ref-7","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031/","/wiki/Digital_object_identifier","http://dx.doi.org/10.1084%2Fjem.174.6.1483","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/1660525","#cite_ref-8","/wiki/International_Standard_Book_Number","/wiki/Special:BookSources/3-7692-3483-9","#cite_ref-phenotypes_9-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2Fs11938-003-0001-1","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12744819","#cite_ref-Present_10-0","/wiki/Lloyd_Mayer","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJM199905063401804","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/10228190","#cite_ref-ACCENT2_11-0","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa030815","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/14985485","#cite_ref-ACCENT1_12-0","#cite_ref-ACCENT1_12-1","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2FS0140-6736%2802%2908512-4","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12047962","#cite_ref-topdown_13-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1053%2Fbega.2003.0361","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12617888","#cite_ref-ACT_14-0","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa050516","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16339095","#cite_ref-15","/wiki/Digital_object_identifier","http://dx.doi.org/10.1164%2Frccm.200607-995OC","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17290043","#cite_ref-16","http://ard.bmj.com/content/61/suppl_2/ii51.abstract","/wiki/Digital_object_identifier","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1766720","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12379622","http://ard.bmj.com/content/61/suppl_2/ii51.abstract","#cite_ref-17","/wiki/Digital_object_identifier","http://dx.doi.org/10.1007%2Fs10227-004-0115-7","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15685387","#cite_ref-18","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16724373","#cite_ref-19","http://www.nejm.org/doi/full/10.1056/NEJMoa011110#t=articleResults","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa011110","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/11596589","http://www.nejm.org/doi/full/10.1056/NEJMoa011110#t=articleResults","#cite_ref-20","http://www.remicade.com/remicade/global/hcp/healthcare_professionals.html","#cite_ref-21","http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf","/wiki/Wikipedia:Link_rot","#cite_ref-22","http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm","/wiki/Food_and_Drug_Administration_(United_States)","http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalproducts/ucm175843.htm","#cite_ref-23","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/10622295","#cite_ref-24","/wiki/The_New_England_Journal_of_Medicine","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJM200103223441207","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/11259725","#cite_ref-25","#cite_ref-26","#cite_ref-27","http://www.rxlist.com/remicade-drug.htm","#cite_ref-28","http://guidance.nice.org.uk/TA40/Guidance","#cite_ref-29","http://www.medicareaustralia.gov.au/provider/pbs/drugs1/crohns.jsp#N10041","/wiki/Template:Immunosuppressants","/wiki/Template_talk:Immunosuppressants","//en.wikipedia.org/w/index.php?title=Template:Immunosuppressants&action=edit","/wiki/Immunomodulator","/wiki/Immunosuppressive_drug","/wiki/Immunosuppressant","/wiki/ATC_code_L04","/wiki/Antimetabolite","/wiki/Purine_synthesis_inhibitor","/wiki/Azathioprine","/wiki/Mycophenolic_acid","/wiki/Pyrimidine_synthesis_inhibitor","/wiki/Leflunomide","/wiki/Teriflunomide","/wiki/Antifolate","/wiki/Methotrexate","/wiki/Macrolide","/wiki/Interleukin_2","/wiki/FKBP","/wiki/Cyclophilin","/wiki/Calcineurin","/wiki/Tacrolimus","/wiki/Ciclosporin","/wiki/Pimecrolimus","/wiki/Abetimus","/wiki/Gusperimus","/wiki/Thalidomide","/wiki/Lenalidomide","/wiki/Interleukin_1_receptor_antagonist","/wiki/Anakinra","/wiki/Mammalian_target_of_rapamycin","/wiki/Sirolimus","/wiki/Everolimus","/wiki/Ridaforolimus","/wiki/Temsirolimus","/wiki/Umirolimus","/wiki/Zotarolimus","/wiki/Antibody","/wiki/Monoclonal_antibodies","/wiki/Complement_component_5","/wiki/Eculizumab","/wiki/TNF_inhibitor","/wiki/Adalimumab","/wiki/Afelimomab","/wiki/Certolizumab_pegol","/wiki/Golimumab","/wiki/Nerelimomab","/wiki/Interleukin_5","/wiki/Mepolizumab","/wiki/Immunoglobulin_E","/wiki/Omalizumab","/wiki/Interferon","/wiki/Faralimomab","/wiki/Interleukin_6","/wiki/Elsilimomab","/wiki/Interleukin_12","/wiki/Interleukin_23","/wiki/Lebrikizumab","/wiki/Ustekinumab","/wiki/CD3_(immunology)","/wiki/Muromonab-CD3","/wiki/Otelixizumab","/wiki/Teplizumab","/wiki/Visilizumab","/wiki/CD4","/wiki/Clenoliximab","/wiki/Keliximab","/wiki/Zanolimumab","/wiki/CD11a","/wiki/Efalizumab","/wiki/CD18","/wiki/Erlizumab","/wiki/CD20","/wiki/Afutuzumab","/wiki/Rituximab","/wiki/Ocrelizumab","/wiki/Pascolizumab","/wiki/CD23","/wiki/Gomiliximab","/wiki/Lumiliximab","/wiki/CD40_(protein)","/wiki/Teneliximab","/wiki/Toralizumab","/wiki/L-selectin","/wiki/Aselizumab","/wiki/CD80","/wiki/Galiximab","/wiki/Basigin","/wiki/Gavilimomab","/wiki/CD154","/wiki/Ruplizumab","/wiki/Belimumab","/wiki/CTLA-4","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Chloramphenicol_acetyltransferase","/wiki/Bertilimumab","/wiki/Lerdelimumab","/wiki/Metelimumab","/wiki/Integrin","/wiki/Natalizumab","/wiki/Interleukin-6_receptor","/wiki/Tocilizumab","/wiki/Lymphocyte_function-associated_antigen_1","/wiki/Odulimomab","/wiki/IL-2_receptor","/wiki/Basiliximab","/wiki/Daclizumab","/wiki/Inolimomab","/wiki/T_cell","/wiki/Zolimomab_aritox","/wiki/Atorolimumab","/wiki/Cedelizumab","/wiki/Fontolizumab","/wiki/Maslimomab","/wiki/Morolimumab","/wiki/Pexelizumab","/wiki/Reslizumab","/wiki/Rovelizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Telimomab_aritox","/wiki/Vapaliximab","/wiki/Vepalimomab","/wiki/Polyclonal_antibodies","/wiki/Anti-thymocyte_globulin","/wiki/Anti-lymphocyte_globulin","/wiki/Fusion_protein","/wiki/CTLA-4","/wiki/Abatacept","/wiki/Belatacept","/wiki/TNF_inhibitor","/wiki/Etanercept","/wiki/Pegsunercept","/wiki/Aflibercept","/wiki/Alefacept","/wiki/Rilonacept","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","/wiki/Template:Monoclonals_for_immune_system","/wiki/Template_talk:Monoclonals_for_immune_system","//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_immune_system&action=edit","/wiki/Monoclonal_antibodies","/wiki/Immune_system","/wiki/Immune_system","/wiki/Immunosuppression","/wiki/Adalimumab","/wiki/Atorolimumab","/wiki/Belimumab","/wiki/Brodalumab","/wiki/Carlumab","/wiki/Dupilumab","/wiki/Eldelumab","/wiki/Fresolimumab","/wiki/Golimumab","/wiki/Lerdelimumab","/wiki/Lirilumab","/wiki/Mavrilimumab","/wiki/Metelimumab","/wiki/Morolimumab","/wiki/Namilumab","/wiki/Oxelumab","/wiki/Placulumab","/wiki/Sarilumab","/wiki/Sifalimumab","/wiki/Tabalumab","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Nivolumab","/wiki/Urelumab","/wiki/Bertilimumab","/wiki/Zanolimumab","/wiki/Afelimomab","/wiki/Elsilimomab","/wiki/Faralimomab","/wiki/Gavilimomab","/wiki/Inolimomab","/wiki/Maslimomab","/wiki/Nerelimomab","/wiki/Odulimomab","/wiki/Telimomab_aritox","/wiki/Vepalimomab","/wiki/Zolimomab_aritox","/wiki/Chimeric_antibody","/wiki/Basiliximab","/wiki/Clenoliximab","/wiki/Galiximab","/wiki/Gomiliximab","/wiki/Keliximab","/wiki/Lumiliximab","/wiki/Priliximab","/wiki/Teneliximab","/wiki/Vapaliximab","/wiki/Humanized_antibody","/wiki/Aselizumab","/wiki/Apolizumab","/wiki/Benralizumab","/wiki/Cedelizumab","/wiki/Certolizumab_pegol","/wiki/Daclizumab","/wiki/Eculizumab","/wiki/Efalizumab","/wiki/Epratuzumab","/wiki/Erlizumab","/wiki/Etrolizumab","/wiki/Fontolizumab","/wiki/Itolizumab","/wiki/Lampalizumab","/wiki/Ligelizumab","/wiki/Mepolizumab","/wiki/Mogamulizumab","/wiki/Natalizumab","/wiki/Ocrelizumab","/wiki/Omalizumab","/wiki/Ozoralizumab","/wiki/Pascolizumab","/wiki/Pateclizumab","/wiki/Pexelizumab","/wiki/Pidilizumab","/wiki/PRO_140","/wiki/Reslizumab","/wiki/Rontalizumab","/wiki/Rovelizumab","/wiki/Ruplizumab","/wiki/Quilizumab","/wiki/Samalizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Teplizumab","/wiki/Tocilizumab","/wiki/Toralizumab","/wiki/Tregalizumab","/wiki/Vatelizumab","/wiki/Vedolizumab","/wiki/Visilizumab","/wiki/TGN1412","/wiki/Ibalizumab","/wiki/Otelixizumab","/wiki/Interleukin","/wiki/Briakinumab","/wiki/Canakinumab","/wiki/Fezakinumab","/wiki/Guselkumab","/wiki/Secukinumab","/wiki/Sirukumab","/wiki/Tralokinumab","/wiki/Ustekinumab","/wiki/Anrukinzumab","/wiki/Clazakizumab","/wiki/Enokizumab","/wiki/Gevokizumab","/wiki/Ixekizumab","/wiki/Lebrikizumab","/wiki/Olokizumab","/wiki/Perakizumab","/wiki/Tildrakizumab","/wiki/Lesion","/wiki/Besilesomab","/wiki/Technetium_(99mTc)_fanolesomab","/wiki/Lemalesomab","/wiki/Technetium_(99mTc)_sulesomab","/wiki/List_of_World_Health_Organization_Essential_Medicines","/wiki/List_of_withdrawn_drugs","/wiki/Clinical_trial","/wiki/Clinical_trial#Phase_III","/wiki/Clinical_trial#Phase_II","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","http://en.wikipedia.org/w/index.php?title=Infliximab&oldid=544512816","/wiki/Help:Categories","/wiki/Category:Centocor","/wiki/Category:TNF_inhibitors","/wiki/Category:Monoclonal_antibodies","/wiki/Category:Engineered_proteins","/wiki/Category:Schering-Plough","/wiki/Category:Immunosuppressants","/wiki/Category:Pages_with_DOIs_inactive_since_2012","/wiki/Category:All_articles_with_dead_external_links","/wiki/Category:Articles_with_dead_external_links_from_November_2009","/wiki/Category:Chemical_compounds_which_do_not_have_a_ChemSpiderID","/wiki/Category:Articles_with_changed_EBI_identifier","/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields","/wiki/Category:Articles_needing_cleanup_from_January_2010","/wiki/Category:All_articles_needing_cleanup","/wiki/Category:Cleanup_tagged_articles_without_a_reason_field_from_January_2010","/wiki/Category:Wikipedia_pages_needing_cleanup_from_January_2010","/wiki/Category:Vague_or_ambiguous_time_from_April_2010","/wiki/Category:Articles_needing_additional_references_from_November_2009","/wiki/Category:All_articles_needing_additional_references","/wiki/Category:All_articles_with_unsourced_statements","/wiki/Category:Articles_with_unsourced_statements_from_March_2009","/w/index.php?title=Special:UserLogin&returnto=Infliximab&type=signup","/w/index.php?title=Special:UserLogin&returnto=Infliximab","/wiki/Infliximab","/wiki/Talk:Infliximab","#","/wiki/Infliximab","/w/index.php?title=Infliximab&action=edit","/w/index.php?title=Infliximab&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","//donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Infliximab","/wiki/Special:RecentChangesLinked/Infliximab","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Infliximab&oldid=544512816","/w/index.php?title=Infliximab&action=info","/w/index.php?title=Special:Cite&page=Infliximab&id=544512816","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Infliximab","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Infliximab&oldid=544512816&writer=rl","/w/index.php?title=Infliximab&printable=yes","//de.wikipedia.org/wiki/Infliximab","//es.wikipedia.org/wiki/Infliximab","//fr.wikipedia.org/wiki/Infliximab","//it.wikipedia.org/wiki/Infliximab","//he.wikipedia.org/wiki/%D7%A8%D7%9E%D7%99%D7%A7%D7%99%D7%99%D7%93","//nl.wikipedia.org/wiki/Infliximab","//ja.wikipedia.org/wiki/%E3%82%A4%E3%83%B3%E3%83%95%E3%83%AA%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96","//pl.wikipedia.org/wiki/Infliksymab","//pt.wikipedia.org/wiki/Infliximabe","//ru.wikipedia.org/wiki/%D0%98%D0%BD%D1%84%D0%BB%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1","//fi.wikipedia.org/wiki/Infliksimabi","//sv.wikipedia.org/wiki/Infliximab","//www.wikidata.org/wiki/Special:ItemByTitle/enwiki/Infliximab","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//www.wikimediafoundation.org/","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","http://en.m.wikipedia.org/wiki/Infliximab","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=skins.vector&only=scripts&skin=vector&*","/w/index.php?title=MediaWiki:Gadget-ReferenceTooltips.js&action=raw&ctype=text/javascript&508635914","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":["immunology","medicine","united_states","tests","pharmacology"],"pdf":["http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf"],"categories":["Centocor","TNF inhibitors","Monoclonal antibodies","Engineered proteins","Schering-Plough","Immunosuppressants"],"headings":["Medical uses","Adverse effects","Pharmacology","Availability/affordability","See also","External links","References"],"image":["//upload.wikimedia.org/wikipedia/commons/thumb/5/5c/Infliximab_structure2.jpg/220px-Infliximab_structure2.jpg","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/0/0e/CD_colitis.jpg/220px-CD_colitis.jpg","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/magnify-clip.png","//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png","//bits.wikimedia.org/static-1.21wmf11/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.21wmf11/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["food_and_drug_administration","united_states"],["food_and_drug_administration","united_states"],["receptor","biochemistry"],["remission","medicine"],["food_and_drug_administration","united_states"],["affinity","pharmacology"],["receptor","immunology"],["specificity","tests"]],"members":["receptor","remission","food_and_drug_administration","specificity","affinity"],"related":["Tumor_necrosis_factors","Reticuloendothelial","International_Nonproprietary_Name","Monoclonal_antibody","TNF_alpha","Autoimmune","List_of_autoimmune_diseases","Centocor","Mitsubishi_Tanabe_Pharma","Xian_Janssen","Schering-Plough","Merck_&_Co","Johnson_&_Johnson","Food_and_Drug_Administration_(United_States)","Psoriasis","Crohn's_disease","Ankylosing_spondylitis","Psoriatic_arthritis","Rheumatoid_arthritis","Ulcerative_colitis","Crohn's_disease","Food_and_Drug_Administration_(United_States)","Cytokine","Receptor_(biochemistry)","Etanercept","Programmed_cell_death","T_lymphocytes","Antibody","Monoclonal_antibody","Jan_Vilcek","New_York_University_School_of_Medicine","Centocor","Golimumab","Adalimumab","Certolizumab_pegol","CD120","Fc_region","Intravenous_therapy","Route_of_administration","Digestive_system","Phenotype","Crohn's_disease","Fistula","Inflammation","Skin","Bowel","Placebo","Peptic_ulcer","Colonoscopy","Prednisone","Remission_(medicine)","Tumour_necrosis_factor","COPD","Behçet's_disease","Enthesitis","Remicade","Enbrel","Humira","Immunosuppressants","Blood_disorder","Infection","Lymphoma","Hepatitis_B","Tuberculosis","Hepatosplenic_T-cell_lymphoma","Lupus","Demyelinating","Central_nervous_system","Psoriasis","Vitiligo","Leukopenia","Neutropenia","Thrombocytopenia","Pancytopenia","Food_and_Drug_Administration_(United_States)","Methotrexate","Azathioprine","Psoriasis","Psoriatic_arthritis","Ankylosing_spondylitis","Rheumatoid_arthritis","TNF_alpha","Affinity_(pharmacology)","T_cells","Adalimumab","Transmembrane","Receptor_(immunology)","The_New_England_Journal_of_Medicine","Adalimumab","Lysing","Specificity_(tests)","Lymphotoxin","Proinflammatory","Cytokine","Interleukin","Leukocyte","Endothelial","Adhesion_molecule","Transgenic","Crohn's_Disease_Activity_Index","Biological_therapy_for_inflammatory_bowel_disease"]}